miR-27a在三阴性乳腺癌中的表达及其对细胞耐药的影响  

Expression of miR-27a in triple-negative breast cancer and its effect on drug resistance

作　　者：杨海松 张萌萌 陈腾祥[2] 徐澍 毛大华 Yang Haisong;Zhang Mengmeng;Chen Tengxlang;Xu Shu;Mao Dahua(Department of Breast Surgery;3 Department of Pathology,tits Affiliated Hospital of Guizhou Medical University,Guizhou Guiyang 550001,Chin;2.Department of Physiology,Guizhou Medieal University,Guizhou Guiyang 550001,China)

机构地区：[1]贵州医科大学附属医院乳腺外科,贵州贵阳550001 [2]贵州医科大学生理学教研室,贵州贵阳550001 [3]贵州医科大学附属医院病理科,贵州贵阳550001

出　　处：《现代肿瘤医学》2018年第19期3049-3054,共6页Journal of Modern Oncology

基　　金：贵州省科技厅基金项目(编号:黔科合J字[2012]2057号)

摘　　要：目的:探讨miR-27a在三阴性乳腺癌(triple-negative breast cancer,TNBC)中的表达及其对细胞耐药的影响。方法:首先通过QRT-PCR检测TNBC细胞株及非TNBC细胞株中miR-27a及P-gp的差异表达;上调TNBC细胞中的miR-27a的表达,通过CCK8检测细胞对化疗药物敏感性的变化。同时收集TNBC患者化疗前后血液标本,将其分为化疗敏感组和化疗耐药组,QRT-PCR检测患者血液标本中miR-27a及P-gp的表达,分析miR-27a与乳腺癌患者预后相关性。结果:miR-27a在TNBC细胞株中的表达明显低于非TNBC细胞株,上调TNBC细胞株中miR-27a的表达能够降低P-gp的表达,增加细胞对化疗药物的敏感性,此外TNBC组中miR-27a的表达与患者组织学分级、临床分期及淋巴结转移相关(P <0. 05);在非TNBC组中miR-27a的表达与患者临床病理特征无明显相关性(P均> 0. 05)。结论:miR-27a参与调节TNBC细胞耐药,miR-27a可作为评估乳腺癌化疗敏感性及临床预后的潜在靶基因。Objective ： To investigate the expression of miR - 27a in triple - negative breast cancer and its effect on drug resistance. Methods ：The expression of miR - 27a and P - gp was detected by QRT - PCR in TNBC cell line and non - TNBC cell line in vitro. The expression of miR -27a in TNBC cells was up - regulated by transfected miR -27a mimics. At the same time to collect TNBC blood samples before and after chemotherapy of breast cancer,which can be divided into chemotherapy group and chemotherapy resistance group, the expression of miR - 27a and P-gp were detected in blood samples by QRT -PCR, miR -27a and the prognosis of patients with breast cancer was analysed. Results ： miR - 27a expression in TNBC cell line was significantly lower than that of non - TNBC cells. Up - regulation of miR -27a expression in TNBC cell line can reduce the expression of P - gp, increase the sensitivity- of cells to chemotherapeutic drugs. The expression of miR - 27a in the TNBC group was related with histological grade, clinical stage and lymph node metastasis （P 〈 0.05）. In the non - TNBC group （ non - triple - negative breast cancer） there was no significant correlation between the expression and clinicopathological characteristics in miR -27a （ P 〉 0.05 ）. Conclusion ： miR - 27a may be involved in the regulation of TNBC breast cancer cell resistance, and miR -27a may be a potential target gene for evaluating chemotherapy sensitivity- and prognosis of breast cancer.

关 键 词：miR-27a P-GP 三阴性乳腺癌 耐药 

分 类 号：R737.9[医药卫生—肿瘤]